[Statins under fire: justified or not?]

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• Clinical Pharmacy

Context:

• Statins are lipid-lowering drugs that inhibit hepatic cholesterol synthesis, reducing LDL cholesterol and triglycerides while modestly increasing HDL cholesterol.
• Beyond lipid modification, statins exhibit pleiotropic effects, including atherosclerotic plaque stabilization, crucial for cardiovascular disease management.
• Historical underrepresentation of women and the elderly in clinical trials has influenced treatment guidelines for cardiovascular disease prevention.

Purpose:

• To review the established efficacy of statins in secondary and primary prevention of cardiovascular diseases.
• To discuss the evolving guidelines regarding statin initiation in specific populations, including the elderly, diabetic patients, and children.
• To highlight the importance of safety profiles, adverse effects, drug interactions, and the role of pharmacists in patient care.

Summary:

• The 4S-study confirmed statin benefits in secondary prevention, while the WOSCOPS-study demonstrated efficacy in primary prevention.
• Current guidelines support statin use in high-risk individuals, including Type 2 diabetic patients with prior cardiovascular events, and consider lowering the age for pediatric initiation.
• Muscle toxicity is a primary concern, exacerbated by drug interactions (e.g., CYP3A4), high doses, and combination therapy; statins are contraindicated in pregnancy.

Impact:

• Statins are essential for managing hyperlipidemia and reducing cardiovascular morbidity and mortality, particularly in high-risk populations.
• Individualized risk assessment is crucial for primary prevention decisions, emphasizing patient education on lifestyle modifications and medication adherence.
• Pharmacists are vital in optimizing statin therapy by advising on risks, benefits, and adherence, thereby improving patient outcomes in cardiovascular care.